NeurAxis, Inc. (NRXS) Deep Dive Video
Summary
A first-to-market, guideline-backed neuromodulation therapy hits a 2026 reimbursement inflection—if NRXS outruns dilution, the upside can be dramatic.
View NRXS stock page · Read the NRXS research report
Loading the video player…